Predictors of radiological progression of rheumatoid arthritis while receiving conventional synthetic disease-modifying antirheumatic drugs
DOI:
https://doi.org/10.14739/mmt.2024.4.311076Keywords:
rheumatoid arthritis, radiological progression, predictorsAbstract
The aim of the work is to study the predictors of rheumatoid arthritis (RA) radiological progression while using conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
Materials and methods. 163 patients with RA who were prescribed csDMARD were included in the study. Most of them were female 141 (86.5 %); mean age was 50.1 ± 12.0 years, disease duration 37.5 ± 56.3 months. Rheumatoid factor (RF) was detected in 53.3 % of patients, and antibodies to cyclic citrullinated peptide (ACCP) – in 54.0 %. Logistic and linear regression were used to analyze independent risk factors for radiological progression of RA and results were expressed as odds ratio (OR). Statistical processing was carried out using SPSS 29.0 software.
Results. During 2 years of study, radiological progression according to the OMERACT 4 criteria was observed in 104 patients (63.8 %): in 97 patients (59.5 %) according to the total van der Heijde’s Sharp score (SHS); 53 (32.5 %) – erosion scale; and 99 (60.7 %) – narrowing scale. The dynamics of the average values of the total SHS and its components (erosive and narrowing scales) were 11.50 ± 14.20 (р < 0.001), 3.29 ± 5.86 (р < 0.01) and 8.30 ± 15.90 (p < 0.001) respectively. The mean increase in total SHS was 5.75 per year, while 41 patients (25.2 %) had radiological remission. In multivariate and ROC analyses, higher titers of ACCP (OR 0.06 [0.05; 0.09]) and RF (OR 0.01 [0.002; 0.02]), as well as the patient’s global assessment by visual analogue scale (OR 0.15 [-0.02; 0.33]) were independently associated with the risk of radiological progression of RA.
Conclusions. The radiological progression of RA is observed in 63.8 % of patients with undergoing csDMARDs therapy. Only one in four patients achieves radiological remission. Independent predictors of radiographic progression in patients with RA are higher titers of ACCP, RF and higher values of patient’s global assessment by visual analogue scale at baseline.
References
Eberhard A, Rydell E, Forslind K, Bergman S, Mandl T, Olofsson T, et al. Radiographic damage in early rheumatoid arthritis is associated with increased disability but not with pain-a 5-year follow-up study. Arthritis Res Ther. 2023;25(1):29. doi: https://doi.org/10.1186/s13075-023-03015-9
Parikh T, Yadav S, Balakrishnan C. Radiological Progression and Predictors of Radiological Progression in Early Rheumatoid Arthritis Treated with Conventional Synthetic Disease-modifying Agents. Indian Journal of Rheumatology. 2024;19(1):11-8. doi: https://doi.org/10.1177/09733698241229936
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010; 62(9):2569-81. doi: https://doi.org/10.1002/art.27584
Møller-Bisgaard S, Hørslev-Petersen K, Ørnbjerg LM, Ejbjerg B, Hetland ML, Møller JM, et al. Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial. RMD Open. 2024;10(1):e003945. doi: https://doi.org/10.1136/rmdopen-2023-003945
Klooster TP, Versteeg LG, Oude Voshaar MA, de la Torre I, De Leonardis F, Fakhouri W, et al. Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Arthritis Res Ther. 2019;21(1):237. doi: https://doi.org/10.1186/s13075-019-2030-8
Park Y, Li ML, Kim JW, Koh JH, Park YJ, Kim WU. Time-integrated Cumulative Parameters Predictive of Radiographic Progression of Rheumatoid Arthritis: Real-world Data From a Prospective Single-center Cohort. J Rheum Dis. 2022;29(2):98-107. doi: https://doi.org/10.4078/jrd.2022.29.2.98
Møller-Bisgaard S, Georgiadis S, Hørslev-Petersen K, Ejbjerg B, Hetland ML, Ørnbjerg LM, et al. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. Rheumatology (Oxford). 2021;60(1):380-91. doi: https://doi.org/10.1093/rheumatology/keaa496
Abdelhafiz D, Baker T, Glascow DA, Abdelhafiz A. Biomarkers for the diagnosis and treatment of rheumatoid arthritis – a systematic review. Postgrad Med. 2023;135(3):214-23. doi: https://doi.org/10.1080/00325481.2022.2052626
Takeuchi T, Soen S, Ishiguro N, Yamanaka H, Tanaka S, Kobayashi M, et al. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Mod Rheumatol. 2021;31(1):34-41. doi: https://doi.org/10.1080/14397595.2019.1703484
van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261-3.
Carpenter L, Norton S, Nikiphorou E, Jayakumar K, McWilliams DF, Rennie KL, et al. Early Rheumatoid Arthritis Study and the Early Rheumatoid Arthritis Network. Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts. Arthritis Care Res (Hoboken). 2017;69(12):1809-17. doi: https://doi.org/10.1002/acr.23217
Versteeg GA, Steunebrink L, Vonkeman HE, Ten Klooster PM, Van Der Bijl AE, Van De Laar M. Early radiological progression remains associated with long-term joint damage in real-world rheumatoid arthritis patients treated to the target of remission. Scand J Rheumatol. 2022;51(2):87-96. doi: https://doi.org/10.1080/03009742.2021.1917161
Iaremenko O, Mykytenko G. Achievement of clinical remission in patients with rheumatoid arthritis depending on the ACCP- and RF-serological status. Georgian Med News. 2021;(318):99-104.
